摘要
目的:探讨ICE方案联合利妥昔单抗对难治性弥漫大B细胞淋巴瘤FOXP1与Livin表达的影响。方法:选取难治性弥漫大B细胞淋巴瘤患者78例,按照治疗方案不同分为对照组和研究组,各39例。对照组采用ICE方案治疗,研究组采用ICE方案联合利妥昔单抗治疗,每21天为1个周期,两组共治疗4个疗程,治疗前后取肿瘤组织切片采用免疫组织化学Envision法检测FOXP1与Livin表达水平,对比两组间临床疗效,同时进行随访,观察和记录生存状况以及不良反应情况。结果对照组治疗有效率71.80%低于研究组89.74%(P<0.05);与治疗前比较,研究组治疗后FOXP1表达阳性率降低(P<0.05),与对照组比较,研究组治疗后FOXP1表达阳性率较低(P<0.05);与治疗前比较,研究组治疗后Livin表达阳性率降低(P<0.05),与对照组比较,研究组治疗后Livin表达阳性率较低(P<0.05);研究组随访第2年、3年生存率(74.36%、66.67%)高于对照组(61.54%、48.72%),有统计学差异(P<0.05);两组间不良反应发生率对比,统计学无差异(P>0.05)。结论:ICE方案联合利妥昔单抗对难治性弥漫大B细胞淋巴瘤疗效确切,降低FOXP1与Livin表达,提高生存率,安全性高。
Objective:To investigate the effect of CHOP combined with rituximab on the expression of FOXP1 and Livin in refractory diffuse large B-cell lymphoma.Methods:78 patients with refractory diffuse large B cell lymphoma form our department were selected and divided into 2 groups,control group(n=39)and study group(n=39).The control group was treated with CHOP regimen.The study group were treated CHOP combined with rituximab treatment,every 21 days for a cycle,the two groups were treated for 4 courses,the expressions of FOXP1 and Livin were detected by immunohistochemistry Envision method.The clinical efficacy of the two groups was compared with that of the two groups.The survival status and the toxicity status were observed and recorded.Results:The effective rate of the control group 71.80% was lower than the study group(89.74%)(P<0.05).Compared with before treatment,the positive rate of FOXP1 expression decreased in 2 groups(P<0.05),compared with the control group,the positive rate of FOXP1 expression was lower in the study group(P<0.05).Compared with before treatment,the positive rate of Livin expression decreased in the study group(P<0.05),compared with the control group,the positive rate of Livin expression was lower in the study group(P<0.05).The 3-year survival rate(74.36%,66.67%)in the study group was higher than that the control group(61.54%,48.72%)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P> 0.05).Conclusion:CHOP combined with rituximab has a good effect on refractory diffuse large B cell lymphoma,reducing the expression of FOXP1 and Livin,improving the survival rate and high safety.
出处
《陕西医学杂志》
CAS
2018年第1期50-52,68,共4页
Shaanxi Medical Journal
基金
河北省沧州市科技计划项目(151302180)
